Patent intelligence · US
US 10220093
Long-acting semi-solid lipid formulations
Long-acting semi-solid lipid formulations
Patent details — US 10220093
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 5, 2019
- Expiration
- Feb 28, 2039
- Applicant
- MIRA PHARMA CORPORATION
- Claims
- 17
- CPC classes
- A61K, A61K31/445, A61K47/14, A61K9/0014
Quick answer
US 10220093 (Long-acting semi-solid lipid formulations) is held by MIRA PHARMA CORPORATION. Status: granted. Granted Mar 5, 2019. Expires Feb 28, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MIRA PHARMA CORPORATION
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K31/445, A61K47/14, A61K9/0014, A61K9/0019, A61K9/06
More from MIRA PHARMA CORPORATION
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 10220093?
US 10220093 (Long-acting semi-solid lipid formulations) is held by MIRA PHARMA CORPORATION. Status: granted. Granted Mar 5, 2019. Expires Feb 28, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10220093?
MIRA PHARMA CORPORATION is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 10220093 expire?
Our index shows an expiration date of Feb 28, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.